close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Psoriasis

Recent news which mentions Psoriasis

Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Tickers ALC JNJ RXST
Tags JNJ pharmaceutical stocks Benzinga
From Benzinga
New Study Looks At Obscure Cannabinoids For Treating Psoriasis, Eczema And Acne
Tickers ACNE
Tags General eczema Polish study
From Benzinga
The Key To Perfect Hair? Myths And Benefits Of CBD For Hair Care
Tickers CBD HAIR
Tags HAIR CBD Market News
From Benzinga
Empowering Psoriasis Patients Through Mental Health Support
Tickers BMY
Tags Health & Healthcare Philanthropy & Cause Initiatives psoriasis
From 3BL Media: Corporate Social Responsibility, Energy and Health News
From Misdiagnosis to Building a Support System: Royce Thomas' Experience Living With Psoriasis
Tickers BMY
Tags NYSE: BMY International Federation of Psoriasis Associations Frida Dunger Johnsson
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Roivant' Dermavant Showcases New Long-Term Durability, Tolerability Data For Plaque Psoriasis Candidate
Tickers ROIV
Tags General Benzinga News
From Benzinga
Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study
Tickers AMGN CANF
Tags Psoriasis Biotech Penny Stocks
From Benzinga
Dermata Therapeutics Shares Plunge 20% Premarket: What Investors Need To Know
Tickers DRMA
Tags General Market News DRMA
From Benzinga
Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows
Tickers CANF
Tags Penny Stocks Psoriasis Biotech
From Benzinga
Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast
Tickers ARQT
Tags Market News News Financing
From Benzinga
Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review
Tickers ARQT
Tags Briefs Psoriasis Biotech
From Benzinga
Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level
Tickers AMGN
Tags General Benzinga Market News
From Benzinga
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022
Tickers AMGN CANF
Tags News Market News General
From Benzinga
vTv Therapeutics Pulls The Plug On Psoriasis Candidate; Cuts Workforce By 65%
Tickers VTVT
Tags News Market News VTVT
From Benzinga
Amgen's Otezla Meets Primary Goal In Late-Stage Genital Psoriasis Study
Tickers AMGN
Tags Phase 3 Trial AMGN Briefs
From Benzinga
Bristol Myers' Deucravacitinib Under FDA Review For Plaque Psoriasis
Tickers AMGN BMY
Tags FDA Health Care Biotech
From Benzinga
Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial
Tickers ZLAB
Tags Psoriasis Briefs Health Care
From Benzinga
Dermata Stock Jumps On Positive Psoriasis Candidate Data
Tickers DRMA
Tags General DRMA Market News
From Benzinga
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis
Tickers ANAB
Tags Psoriasis Briefs Health Care
From Benzinga
Novartis Posts New Data Reinforcing Efficacy, Convenience Of Cosentyx Autoinjector In Psoriasis
Tickers NVS
Tags NVS Phase 3 Trial Biotech
From Benzinga
Evelo Biosciences Psoriasis Candidate Shows Benefit In Mid-Stage Study
Tickers EVLO
Tags General Market News News
From Benzinga
vTv Therapeutics Stock Gains As Psoriasis Candidate Shows Favorable Safety Profile
Tickers VTVT
Tags Briefs Health Care Trading Ideas
From Benzinga
Why Are Dermata Therapeutics Shares Trading Higher Today?
Tickers ACNE DRMA
Tags Analyst Ratings acne Benzinga
From Benzinga
Soligenix To Test Synthetic Hypericin In Psoriasis Patients
Tickers SNGX
Tags News Market News General
From Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
Tickers NVS UCBJF UCBJY
Tags Briefs Health Care Trading Ideas
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today